Myeloid-derived suppressor cells and tumor: Current knowledge and future perspectives.

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Tumor lesions exhibit immunosuppressive properties, hindering effective cancer immunotherapy.
• Chronic inflammation, driven by stromal and tumor cells, generates immunosuppressive factors.
• These factors induce myeloid-derived suppressor cells (MDSCs), key mediators of tumor immunosuppression.

Purpose of the Study:

• To review recent findings on the role of MDSCs in tumor progression.
• To discuss potential therapeutic strategies targeting MDSCs for cancer treatment.

Main Methods:

• Literature review of studies on MDSCs in cancer progression and immunotherapy.
• Analysis of clinical data correlating MDSC frequency with cancer stage and therapeutic response.

Main Results:

• MDSCs are crucial for tumor immunosuppression, requiring direct cell-to-cell contact for function.
• Peripheral blood MDSC frequency correlates with clinical stage and treatment outcomes in various cancers.
• MDSCs contribute to chemoresistance in cancer settings.

Conclusions:

• Blocking the cycle of MDSC development and infiltration is a rational therapeutic approach.
• Targeting MDSCs holds potential for future clinical trials to improve cancer therapy.